Skip to main content
Kinarus Therapeutics Holding AG logo

Kinarus Therapeutics Holding AG — Investor Relations & Filings

Ticker · KNRS ISIN · CH1330780979 LEI · 506700VDL70GGMHR5758 SW Manufacturing
Open in API
Filings indexed 67 across all filing types
Latest filing 2025-09-15 Earnings Release
Country CH Switzerland
Listing SW KNRS

About Kinarus Therapeutics Holding AG

https://www.curatis.com/

Formerly Kinarus Therapeutics Holding AG, the company now operates as Curatis Holding AG, a specialty pharmaceutical company focused on the acquisition, development, and commercialization of innovative medicines for rare and specialty care diseases. The company's operations are divided into two segments. The distribution business acquires, licenses, and distributes third-party medicines for orphan and specialty diseases. The development business advances a pipeline of novel drug candidates, prioritizing compounds with existing safety and efficacy data to accelerate development. Key development programs target conditions such as peritumoral brain edema, severe migraine with aura, and medication overuse headache.

Recent filings

Filing Released Lang Actions
Curatis: Double-digit growth in core business and development milestone achieved for C-PTBE-01
Earnings Release Classification · 100% confidence The document is an 'Ad hoc announcement' from Curatis Holding AG detailing H1 2025 financial results, including revenue, loss, and cash flow figures. It explicitly mentions that for a more detailed discussion, the reader should refer to the 'half-year report' available on their website. Since this document is a summary announcement of financial results rather than the full report itself, it falls under the Earnings Release category. H1 2025
2025-09-15 English
Curatis: Double-digit growth in core business and development milestone achieved for C-PTBE-01
Earnings Release Classification · 100% confidence The document is an 'ad hoc announcement' regarding 'Half Year Results' for Curatis Holding AG. It provides key financial highlights (revenues, operating results, loss for the period) for the first half of 2025. While it mentions that a more detailed half-year report is available on the company website, the document itself serves as the initial public release of these financial results, which fits the definition of an Earnings Release (ER). H1 2025
2025-09-15 English
Curatis expands distribution business with Phoenix Labs with up to CHF 5m additional annual revenues
Regulatory Filings Classification · 100% confidence The document is a media release announcing a new distribution contract between Curatis Holding AG and Phoenix Labs. It details business expansion and revenue expectations but does not fit into specific categories like financial reports, proxy statements, or director dealings. As it is a general corporate announcement regarding business operations, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback.
2025-09-05 English
Curatis expands distribution business with Phoenix Labs with up to CHF 5m additional annual revenues
Regulatory Filings Classification · 100% confidence The document is a media release announcing a new distribution contract between Curatis Holding AG and Phoenix Labs. It describes business expansion and revenue expectations. Since it is a general corporate announcement regarding business operations that does not fit into specific categories like M&A, earnings, or dividends, it is classified as a general regulatory filing/news announcement.
2025-09-05 English
FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study
Legal Proceedings Report Classification · 99% confidence The document is a media release issued by Curatis Holding AG regarding a regulatory update (FDA Type B meeting) for a clinical trial. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding business operations and regulatory progress, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback.
2025-07-31 English
FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study
Legal Proceedings Report Classification · 99% confidence The document is a media release from Curatis Holding AG regarding a regulatory update (FDA Type B meeting) concerning a clinical trial. It does not fit into specific categories like financial reports, dividends, or share transactions. As it is a general corporate announcement regarding business operations and regulatory status, it falls under the 'Regulatory Filings' (RNS) category.
2025-07-31 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.